Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

MediWound (MDWD) EBITDA: 2011-2024

Historic EBITDA for MediWound (MDWD) over the last 14 years, with Dec 2024 value amounting to -$30.2 million.

  • MediWound's EBITDA rose 74.14% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 139.06%. This contributed to the annual value of -$30.2 million for FY2024, which is 349.06% down from last year.
  • According to the latest figures from FY2024, MediWound's EBITDA is -$30.2 million, which was down 349.06% from -$6.7 million recorded in FY2023.
  • Over the past 5 years, MediWound's EBITDA peaked at -$6.7 million during FY2023, and registered a low of -$30.2 million during FY2024.
  • Moreover, its 3-year median value for EBITDA was -$19.6 million (2022), whereas its average is -$18.8 million.
  • As far as peak fluctuations go, MediWound's EBITDA surged by 65.64% in 2023, and later plummeted by 349.06% in 2024.
  • Yearly analysis of 5 years shows MediWound's EBITDA stood at -$9.2 million in 2020, then crashed by 46.76% to -$13.5 million in 2021, then plummeted by 44.75% to -$19.6 million in 2022, then spiked by 65.64% to -$6.7 million in 2023, then crashed by 349.06% to -$30.2 million in 2024.